Efficacy Comparison of 2 Low-dose Atropine Eye Drops in Vietnamese Children Myopia Management

NCT ID: NCT05803863

Last Updated: 2023-04-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-15

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to compare the efficacy of 2 low-dose atropine drops (0,01%; 0,05%) in Vietnamese children. The main questions it aims to answer are:

1. How is the difference in efficacy among 3 groups: atropine 0,01% vs 0,05% vs spectacles?
2. How is the difference in side effects among 3 groups: atropine 0,01% vs 0,05% vs spectacles?
3. How is the difference in rebound phenomena between 2 atropine groups?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is prospective, comparative, open label. Participants are Vietnamese children. Prescribing drops : 1 drops/eye/night/ 12 months Wash-out: 12 months The atropine drops in this study are commercially available.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Prospective, comparative, open label
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Myatro

Prescribing one 0,01% Myatro (Atropine) drop/eye/night , in 12 months Then wash-out in next 12 months

Group Type EXPERIMENTAL

Myatro

Intervention Type DRUG

myopia control with 0.01% atropine drops

Myatro XL

Prescribing one 0,05% Myatro XL (Atropine) drop/eye/night , in 12 months Then wash-out in next 12 months

Group Type EXPERIMENTAL

Myatro XL

Intervention Type DRUG

myopia control with 0.05% atropine drops

Conventional spectacles

Prescribing conventional spectacles and follow-up in 24 months.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Myatro

myopia control with 0.01% atropine drops

Intervention Type DRUG

Myatro XL

myopia control with 0.05% atropine drops

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Atropine 0.01% Atropine 0.05%

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* myopic 2 eyes (SE above from -0.75 D, astigmatism below -1.50D)
* 8 - 13 years old
* Vietnamese, speaking Vietnamese
* BCVA from 8/10 each eye

Exclusion Criteria

* Using any contact lens in less than 3 months
* Other eye diseases than myopia
* History of eye trauma, surgeries
* Having chronic systemic diseases or having medications affecting eye.
* Having contraindications of atropine drops
* Pre-known allergies to atropine drops
* Undergoing another myopia control treatments
Minimum Eligible Age

8 Years

Maximum Eligible Age

13 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Medicine and Pharmacy at Ho Chi Minh City

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Thi Mong Dung Nguyen

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dung TM Nguyen, MD

Role: PRINCIPAL_INVESTIGATOR

University of Medicine and Pharmacy at Ho Chi Minh City

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Medical Center HCMC

Ho Chi Minh City, , Vietnam

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Vietnam

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dung TM Nguyen, MD

Role: CONTACT

(+84) 982 701 459

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dung TM Nguyen, MD

Role: primary

(+84) 982 701 459

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

137221050

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Low-dose Atropine for Myopia Control in Children
NCT03865160 ACTIVE_NOT_RECRUITING PHASE2/PHASE3
Low-Dose Atropine for Treatment of Myopia
NCT03334253 COMPLETED PHASE3